A Generational Opportunity in a $248B Market

Investor Relations.

Delivering 70× superior pathogen reduction in a $248B market, Illumisoft combines a validated IP moat with an attractive valuation gap against legacy competitors to redefine global biological safety.

Why Invest

Investment Highlights.

Four compelling reasons why Illumisoft represents a unique investment opportunity in the infection prevention space.

  1. The Market Arbitrage
    Illumisoft offers a compelling entry at ~$7.8M USD post-money. Compare this to R-Zero, who raised $170M USD using conventional UVC technology. We offer superior technology at approximately 4% of their implied valuation.

    • $248B Market 2024
    • $473B Market 2034
    • 9.9% HAI CAGR

  2. IP & Clinical Validation
    Our portfolio is defended by 19+ patents. University of Leeds validated as “best performing UV device tested.” Our breakthrough Far-UVC technology is validated to be 70× more powerful in pathogen reduction while remaining safe for human occupancy.

    • 19+ Patents
    • 99.7% Kill Rate
    • 70× More Powerful

  3. The Execution Engine
    We hold the First Health Canada Registration for an upper-room GUV device. This regulatory first-mover advantage streamlines our path to FDA 510(k) and CE Marking while achieving 60% gross margins.

    • 60% Gross Margin
    • 24 Day Payback
    • 1st HC Approval

  4. Path to Liquidity
    Phase 1 commercialization targets 6,500 hospitals in North America. Key catalysts include TSX-V listing, Tier-1 hospital contracts, and FDA 510(k) filing. Establishing Far-UVC as critical building infrastructure.

    • $248B Market 2024
    • $473B Market 2034
    • 9.9% HAI CAGR

Massive Market Opportunity.

The global infection control market is experiencing unprecedented growth, driven by regulatory changes and heightened awareness of indoor air quality.

  • $248B Global Infection Control Market (2024)
  • $473B Projected Market Size (2034)
  • $38.5B HAI Control Market (Immediate TAM)
  • 6.7% Market CAGR Growth Rate

Canada’s Healthcare-Acquired Infection Crisis.

Canada has the worst HAI rate in the OECD at 10.5% vs. 3% best practice. The consequences are catastrophic: 4,000+ deaths in Ontario LTC facilities alone, over $1 billion in combined lawsuits, and $29.3B in annual costs.
Canada responded by becoming the first nation to mandate engineered infection prevention standards through CSA Z8000:24 and CSA Z317.12:25.
Illumisoft is the only Canadian company with Health Canada-registered technology positioned to capture this market.

  • Annual HAIs in Canada: 473,590
  • Annual Deaths: 33,151
  • Annual Economic Cost: $29.3B
  • 30-Year ROI: 44,741%

Strategic Investors.

Mission-aligned investors committed to transforming global public health through breakthrough technology.

“The pandemic exposed the critical need for effective indoor air disinfection. Illumisoft's technology represents a real breakthrough that could fundamentally change how we protect indoor spaces.”

“Far-UVC is one of the most important public health innovations of our time. Illumisoft is leading the charge with technology that makes practical what was previously impossible.”

Strategic Ownership

19.43% Held via Resilience Reserve LLC
Chris Anderson (TED) · Rob Reid

Investor Documents.

Access our latest investor materials, financial reports, and corporate documents.

Understand the Illumisoft story.